Articles related to LUNG CANCER

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

The FDA advisory committee’s decision highlights the complexities of perioperative treatment in NSCLC and the need for more precise efficacy data to guide clinical decision-making.

A study on palliative care for advanced lung cancer patients shows that telehealth can match in-person visits in improving quality of life and patient satisfaction. These findings support the broader implementation of telehealth in oncology.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

Explore the indicators of lung cancer, including persistent cough and unexplained weight loss, which may help in its early detection and improve patient outcomes.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.